Open AccessRifampin Pharmacokinetics/Pharmacodynamics in the Hollow-Fiber Model of Mycobacterium kansasii Infection
Author(s) -
Shashikant Srivastava,
Gunavanthi D. Boorgula,
JannYuan Wang,
HsiaoLing Huang,
Dave Howe,
Tawanda Gumbo,
Scott K Heysell
Publication year - 2022
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.02320-21
Subject(s) - ethambutol , mycobacterium kansasii , medicine , isoniazid , regimen , pharmacodynamics , sputum , pharmacokinetics , minimum inhibitory concentration , pharmacology , gastroenterology , microbiology and biotechnology , mycobacterium tuberculosis , antibiotics , tuberculosis , biology , pathology
There is limited high-quality evidence to guide the optimal treatment ofMycobacterium kansasii pulmonary disease. We retrospectively collected clinical data from 33 patients withM. kansasii pulmonary disease to determine the time-to-sputum culture conversion (SCC) upon treatment with a standard combination regimen consist of isoniazid-rifampin-ethambutol. Next, MIC experiments with 20 clinical isolates were performed, followed by a dose-response study with the standard laboratory strain using the hollow-fiber system model ofM. kansasii infection (HFS-Mkn ). The inhibitory sigmoid maximum effect (E max ) model was used to describe the relationship between the bacterial burden and rifampin concentrations.